Transforming growth factor beta1 protein and mRNA levels in inflammatory bowel diseases: towards solving the contradictions by longitudinal assessment of the protein and mRNA amounts

• Autorzy: Liberek A. , Kmiec Z. , Wierzbicki P. M. , Jakobkiewicz-Banecka J. , Liberek T. , Luczak G. , Plata-Nazar K. , Slominska-Fraczek M. , Kaszubowska L. , Gabik-Ciminska M. , Wegrzyn A.
• Języki publikacji: EN

Abstrakty

EN

Previously published studies on levels of the transforming growth factor-β1 (TGF-β1) protein and mRNA of the corresponding gene in patients suffering from inflammatory bowel diseases (IBD) gave varying results, leading to contradictory conclusions. To solve the contradictions, we aimed to assess longitudinally TGF-β1 protein and mRNA levels at different stages of the disease in children suffering from IBD. The study group consisted of 19 pediatric patients with IBD at the age between 3.5 and 18.4 years. The control group consisted of 42 children aged between 2.0 and 18.0 years. The plasma TGF-β1 concentration was measured with ELISA. mRNA levels of the TGF-β1 gene isolated from samples of the intestinal tissue were assessed by reverse transcription and real-time PCR. Levels of TGF-β1 protein in plasma and corresponding mRNA in intestinal tissue were significantly higher in IBD patients than in controls. TGF-β1 and corresponding transcripts were also more abundant in plasma and intestinal tissue, respectively, in patients at the active stage of the disease than during remission. In every single IBD patient, plasma TGF-β1 level and mRNA level in intestinal tissue was higher at the active stage of the disease than during remission. Levels of TGF-β1 and corresponding mRNA are elevated during the active stage of IBD but not during the remission. Longitudinal assessment of this cytokine in a single patient may help to monitor the clinical course of IBD.

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2013
• Tom: 60
• Numer: 4
• Opis fizyczny: p.683-688,fig.,ref.

Twórcy

autor

Liberek A.

• Faculty of Health Sciences with Subfaculty of Nursing, Medical University of Gdansk, Gdansk, Poland

autor

Kmiec Z.

• Department of Histology, Medical University of Gdansk, Gdansk, Poland

autor

Wierzbicki P. M.

• Department of Histology, Medical University of Gdansk, Gdansk, Poland

autor

Jakobkiewicz-Banecka J.

• Department of Molecular Biology, University of Gdansk, Gdansk, Poland

autor

Liberek T.

• Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland

autor

Luczak G.

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdansk, Poland

autor

Plata-Nazar K.

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdańsk, Gdansk, Poland

autor

Slominska-Fraczek M.

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdansk, Poland

autor

Kaszubowska L.

• Department of Histology, Medical University of Gdańsk, Gdansk, Poland

autor

Gabik-Ciminska M.

• Laboratory of Molecular Biology (affiliated with University of Gdansk), Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Gdansk, Poland

autor

Wegrzyn A.

• Department of Microbiology, University of Szczecin, Szczecin, Poland

Bibliografia

• Babyatsky MW, Rossiter G, Podolsky DK (1996) Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984. 
• Bommireddy R, Pathak LJ, Martin J et al. (2006) Self-antigen recognition by TGF β1-deficient T cells causes their activation and systemic inflammation. Lab Invest 86: 1008-1019. 
• Burke JP, Ferrante M, Dejaegher K et al. (2008) Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 14: 1197-1204. 
• di Mola FF, Friess H, Scheuren A et al. (1999) Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 229: 67-75. 
• Heldin CH, Landström M, Moustakas A (2009) Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelialmesenchymal transition. Curr Opin Cell Biol 21: 166-176. 
• Hyams JS, Ferry GD, Mandel FS et al. (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12: 439-447. 
• IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (2005) Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr 41: 1-7. 
• Kader HA, Tchernev VT, Satyaraj E et al. (2005) Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 100: 414-423. 
• Kilic ZMY, Ayaz S, Ozin Y et al. (2009) Plasma transforming growth factor-β1 level in inflammatory bowel disease Turk J Gastroenterol 20: 165-170. 
• Li MO, Wan YY, Sanjabi S, et al. (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146. 
• Liberek A, Jakóbkiewicz-Banecka J, Kloska A et al. (2011) Clinical parameters of inflammatory bowel disease in children do not correlate with four common polymorphisms of the transforming growth factor β1 gene. Acta Biochim Pol 58: 641-644. 
• Liberek A, Kmieć Z, Kartanowicz D et al. (2013) The mRNA level of the transforming growth factor β1 gene, but not the amount of the gene product, can be considered as a potential prognostic parameter in inflammatory bowel diseases in children. Int J Colorectal Dis 28: 165-172. 
• MacDonald TT, Bell I, Monteleone G (2011) The opposing roles of IL-21 and TGFβ1 in chronic inflammatory bowel disease. Biochem Soc Trans 39: 1061-1066. 
• Rahimi RA, Leof EB (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102: 593-608. 
• Sambuelli A, Diez RA, Sugai E et al. (2000) Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment Pharmacol Ther 14: 1443-1449. 
• Saxena V, Lienesch DW, Zhou M et al. (2008) Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol 180: 1903-1912. 
• Scarpa M, Bortolami M, Morgan SL et al. (2009) TGF-β1 and IGF-1 production and recurrence of Crohn's disease after ileo-colonic resection. J Surg Res 152: 26-34. 
• Stadnicki A, Machnik G, Klimacka-Nawrot E et al. (2009) Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis. Int Immunopharmacol 9: 761-766. 
• Sturm A, Schulte C, Schatton R et al. (2000) Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 12: 445-450. 
• Truelove SC, Witts LJ (1954) Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 2: 375-378. 
• Wedrychowicz A, Kowalska-Duplaga K, Jedynak-Wasowicz U et al. (2011) Serum concentrations of VEGF and TGF-β1 during exclusive enteral nutrition in IBD. J Pediatr Gastroenterol Nutr 53: 150-155. 
• Xian CJ, Xu X, Mardell CE et al. (1999) Site-specific changes in transforming growth factor-alpha and -beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand J Gastroenterol 34: 591–600.